Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, March 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 1 citation of this research output.

1

The most recent citing publication is shown below. View this citation on Dimensions.

Short-duration bendamustine ready-to-dilute product in CLL/NHL: clinical and economic advantages

Article in PharmacoEconomics & Outcomes News (April 2021)